NFX

Nuformix plc

Nuformix to investigate a new formulation of NXP002

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update in relation to the Company’s NXP002 asset, a new form of

Nuformix plc

What are the symptoms of pulmonary fibrosis?

The different types of pulmonary fibrosis have similar symptoms. On this page we explain what they are. The main symptoms of pulmonary fibrosis are: breathlessness a cough that doesn’t go

Nuformix plc

Top 10 Cancers of America

Here are the most common cancers in the United States. Most of these statistics were compiled in the American Cancer Society Facts & Figures annual report for 2013: 1 – Skin

Nuformix plc

The Definition of Cancer

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body.  Cancer can start almost anywhere in the human body,

Nuformix plc

Nuformix updates on the Company’s assets

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update on the Company’s assets and other corporate matters.

Nuformix plc

Celebrating 20 years of Cancer.Net

Diane Blum, MSW, FASCO, served as executive director of CancerCare and chief executive officer of the Lymphoma Research Foundation. Originally trained as a social worker, she worked at Dana Farber

Nuformix plc

Risk factors for IPF

Pulmonary fibrosis (PF) is a disease of the respiratory system caused by scarring (fibrosis) in the lungs, which makes it harder for patients to breathe. Based on the underlying cause of the scarring, PF

Nuformix plc

NXP004

Nuformix has discovered novel forms of an undisclosed marketed oncology drug that has significant sales (more than £1 billion per annum in 2020) and is showing further growth We filed

STRIX GROUP PLC ORD 1P
Strix Group plc CEO Mark Bartlett discusses the company's focus on safety controls, global reach, innovation, and growth opportunities for investors.
Firering Strategic MineralS PLC
Learn about Firering Strategic Minerals plc's operations and future plans from an exclusive interview with their Independent Non-Executive Director, Vassilios Carellas.
Pulsar Helium Inc
Discover insights into the helium sector as Stephane Foucard delves into the projects of junior companies, assessing key criteria for commercial viability.
Golden Matrix Group Inc
Golden Matrix Group Inc. CEO Brian Goodman discusses revenue growth, acquisitions, and global markets in an exclusive interview with DirectorsTalk.
XP Factory plc
XP Factory plc's CEO discusses financial highlights, growth targets, and a £10 million credit facility with Barclays in an exclusive interview with DirectorsTalk.